Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 61,288 shares of the biotechnology company's stock, valued at approximately $643,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.12% of REGENXBIO at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. Integral Health Asset Management LLC boosted its holdings in shares of REGENXBIO by 25.0% in the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock worth $11,115,000 after acquiring an additional 190,000 shares during the period. Quest Partners LLC boosted its position in shares of REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company's stock valued at $491,000 after acquiring an additional 41,645 shares during the period. Squarepoint Ops LLC increased its holdings in REGENXBIO by 630.9% during the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company's stock worth $1,711,000 after acquiring an additional 126,249 shares during the period. Acadian Asset Management LLC bought a new position in REGENXBIO in the 2nd quarter valued at $494,000. Finally, Cubist Systematic Strategies LLC grew its position in shares of REGENXBIO by 73.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,235 shares of the biotechnology company's stock valued at $2,202,000 after purchasing an additional 79,655 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
RGNX has been the subject of several research analyst reports. Barclays dropped their price objective on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, August 5th. Morgan Stanley reiterated an "overweight" rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Chardan Capital restated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Raymond James reiterated an "outperform" rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, HC Wainwright cut their price target on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating for the company in a research note on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $35.27.
Check Out Our Latest Analysis on REGENXBIO
Insider Activity
In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares of the company's stock, valued at $114,101.46. This represents a 46.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 13.13% of the stock is currently owned by corporate insiders.
REGENXBIO Stock Performance
NASDAQ:RGNX traded down $0.09 during trading hours on Friday, reaching $9.92. The company's stock had a trading volume of 263,674 shares, compared to its average volume of 623,266. The firm has a 50-day simple moving average of $10.01 and a 200-day simple moving average of $11.89. REGENXBIO Inc. has a 1 year low of $8.53 and a 1 year high of $28.80. The firm has a market capitalization of $491.44 million, a price-to-earnings ratio of -2.03 and a beta of 1.23.
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
